homocysteine and levodopa

homocysteine has been researched along with levodopa in 97 studies

Research

Studies (97)

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (1.03)	18.7374
1990's	2 (2.06)	18.2507
2000's	51 (52.58)	29.6817
2010's	32 (32.99)	24.3611
2020's	11 (11.34)	2.80

Authors

Authors	Studies
Fuller, RW; Hemrick-Leucke, SK; Perry, KW	1
Joseph, JA; Miller, JW; Nadeau, MR; Selhub, J; Shukitt-Hale, B; Villalobos-Molina, R	1
Fowler, B; Kuhn, W; Müller, T; Werne, B	1
Kowa, H; Nakashima, K; Nakaso, K; Takeshima, T; Yasui, K	2
Brattström, L	1
Hummel, T; Kuhn, W; Müller, T; Woitalla, D	1
Müller, T	3
Blandini, F; Fancellu, R; Mangiagalli, A; Martignoni, E; Nappi, G; Pacchetti, C; Samuele, A	1
Fowler, B; Hauptmann, B; Kuhn, W; Müller, T; Woitalla, D	1
Fowler, B; Kuhn, W; Müller, T; Woitalla, D	1
Diaz-Arrastia, R; Frol, AB; Rogers, JD; Sanchez-Saffon, A	1
Kowa, H; Kusumi, M; Nakashima, K; Nakaso, K; Sasaki, K; Takeshima, T; Ueda, K; Yasui, K; Yoshimoto, Y	1
Feldman, RG; Miller, JW; Nadeau, MR; Selhub, J; Thomas, CA; Wolf, PA	1
Lökk, J	1
Di Rocco, A; Werner, P	1
Fuchs, D; Leblhuber, F; Schroecksnadel, K	1
Diaz-Arrastia, R; O'Suilleabhain, P	1
Kuhn, W; Müller, T; Renger, K	1
Brosnan, JT; Brosnan, ME; Jacobs, RL; Stead, LM	2
Lang, AE; Postuma, RB	1
Armenise, E; de Mari, M; Fraddosio, A; Iliceto, G; Lamberti, P; Livrea, P; Zoccolella, S	1
Helkamaa, T; Larjonmaa, H; Nissinen, E; Nissinen, H; Rauhala, P; Reenilä, I; Väänänen, A	1
Hefter, H; Hueber, R; Jost, WH; Leenders, KL; Müller, T; Odin, P; Schwarz, J	1
Armenise, E; de Mari, M; Fraddosio, A; Iliceto, G; Lamberti, P; Lamberti, SV; Livrea, P; Mastronardi, R; Zoccolella, S	1
Armenise, E; de Mari, M; Fraddosio, A; Iliceto, G; Lamberti, P; Lamberti, SV; Livrea, P; Zoccolella, S	1
Bronstein, J; Guarnieri, M; Hubble, J; Kang, GA; Ostrem, JL; Rabinowicz, AL; Subramanian, I	1
Benetin, J; Blazícek, P; Gmitterová, K; Kukumberg, P; Valkovic, P; Valkovicová, L	1
Bostantjopoulou, S; Frangia, T; Hatzizisi, O; Katsarou, Z; Kazis, A; Kiosseoglou, G; Kyriazis, G; Papazisis, K	1
Armenise, E; de Mari, M; Defazio, G; Diroma, C; Fraddosio, A; Iliceto, G; Lamberti, P; Lamberti, SV; Livrea, P; Zoccolella, S	1
Iwamoto, J; Kanoko, T; Sato, Y; Satoh, K	1
Bottiglieri, T; Diaz-Arrastia, R; Greenberg, SM; Growdon, JH; Gurol, ME; Hyman, BT; Irizarry, MC; Locascio, JJ; Raju, S; Tennis, M	1
Kuhn, W; Müller, T	3
Dzoljić, E; Kostić, V; Krajinović, M; Mirković, D; Nesić, Z; Novaković, I; Prostran, M; Stojanović, R; Todorović, Z	1
Armenise, E; de Mari, M; Defazio, G; Dell'Aquila, C; Diroma, C; Fraddosio, A; Iliceto, G; Lamberti, P; Lamberti, SV; Livrea, P; Zoccolella, S	1
Barcikowska, M; Chodakowska-Zebrowska, M; Czyzewski, K; Lokk, J; Peplonska, B; Religa, D; Stepien, K; Styczynska, M; Winblad, B	1
Camicioli, R; Espay, AJ; Lafontaine, AL; Lang, AE; Martin, WR; Postuma, RB; Ranawaya, R; Suchowersky, O; Zadikoff, C	1
Defazio, G; Lamberti, P; Livrea, P; Martino, D; Zoccolella, S	1
Henninger, N; Krause, M; Okun, JG; Schwab, S; Wang, Q	1
Aydemir, T; Cetin, S; Hanoglu, L; Koldas, M; Meral, H; Ozer, F; Ozturk, O; Seval, H; Yilsen, M	1
Blandini, F; Martignoni, E; Nappi, G; Pacchetti, C; Tassorelli, C; Zangaglia, R	1
Armstrong, VW; Bachmann, CG; Guth, N; Happe, S; Helmschmied, K; Paulus, W	1
Belcastro, V; Caccamo, D; Calabresi, P; Currò, M; Di Iorio, W; Gorgone, G; Ientile, R; Menichetti, C; Parisi, G; Parnetti, L; Pisani, F; Rossi, A	1
Brown, MS; Furtado, S; Suchowersky, O; Toth, C; Zochodne, D	1
Bouchard, TP; Camicioli, RM; Somerville, MJ	1
Hlustik, P; Kanovsky, P; Langova, K; Nevrly, M; Vranova, H	2
Barchak, AG; Busanello, EN; Camargo, D; Carrion, MJ; da Costa, JC; Dalbem, A; de Mello Rieder, CR; de Sousa Miguel, SR; dos Santos, EF; Miglioranza, A; Rosa, C; Saute, J; Vargas, CR; Wajner, M; Zanatta, A	1
Abruzzese, G; Antonini, A; Bonuccelli, U; Canesi, M; Cristina, S; Defazio, G; dell'Aquila, C; Lamberti, P; Livrea, P; Logroscino, G; Marchese, R; Pacchetti, C; Zagaglia, R; Zoccolella, S	1
Muhlack, S; Müller, T	2
Chiang, TR; Ho, CS; Hu, CJ; Hung, YL; Sheu, JJ; Tseng, IJ; Yeh, CY; Yu, JM; Yuan, RY	1
Barone, P; De Bonis, ML; Galletti, P; Ingrosso, D; Longo, K; Pellecchia, MT; Russo, A; Salvatore, A; Tedeschi, G; Tessitore, A; Zappia, V	1
Litvinenko, IV; Mogil'naya, VI; Odinak, MM; Perstnev, SV	1
Chun, S; Chung, SJ; Kim, BJ; Kim, GS; Kim, HK; Kim, MJ; Kim, SR; Koh, JM; Lee, MC; Lee, SH; Ryu, JS	1
Belcastro, V; Calabresi, P; Castrioto, A; Gorgone, G; Ientile, R; Menichetti, C; Pierguidi, L; Pisani, F; Rossi, A; Tambasco, N	1
Abe, T; Isobe, C; Terayama, Y	1
Antonini, A; Bareggi, SR; Bondiolotti, G; Natuzzi, F	1
Iliceto, G; Lamberti, P; Lamberti, SV; Logroscino, G; Santamato, A; Zoccolella, S	1
Bengel, G; Ebersbach, G; Ehret, R; Jugel, C; Klostermann, F; Muhlack, S; Müller, T	1
Muhlack, S; Müller, T; Woitalla, D	1
Garlipp, CR; Gobbi, LT; Gobbi, S; Nascimento, CM; Santos, RF; Stella, F	1
Belcastro, V; Caccamo, D; Calabresi, P; Currò, M; Ferlazzo, N; Gorgone, G; Ientile, R; Parisi, G; Parnetti, L; Pisani, F; Rossi, A; Tambasco, N	1
Ahn, YH; Lee, PH; Paik, MJ; Park, HJ; Shin, JY; Sohn, YH	1
Hu, LF; Hu, XW; Li, D; Liu, CF; Qin, SM	1
Li, Q; Liu, W; Sun, YN; Wang, Y; Yang, JF; Zhang, BS; Zhang, W; Zhao, P	1
Abbruzzese, G; Bandettini di Poggio, M; Barone, P; Bonuccelli, U; Borelli, P; Ceravolo, R; Contu, P; Cossu, G; Frosini, D; Iodice, R; Lopiano, L; Manca, D; Manganelli, F; Marchese, R; Melis, M; Mereu, A; Merola, A; Nicoletti, V; Paribello, A; Picillo, M; Santoro, L; Zibetti, M	1
Antonini, A; Calandrella, D; Cantello, R; Coletti Moja, M; Comi, C; Dal Fante, M; Lacerenza, M; Mancini, F; Manfredi, L; Oggioni, GD; Pacchetti, C; Riboldazzi, G; Tunesi, S	1
Ludwichowska, A; Szabat, K; Szadejko, K; Sławek, J	1
Camicioli, R; Emery, D; Gee, M; Sabino, J; Sapkota, S	1
Hong, JM; Lee, JS; Lee, PH; Yong, SW; Yoon, JH	1
Bhattacharjee, N; Borah, A; Choudhury, A; Choudhury, S; Mazumder, MK; Paul, R	1
Cao, LD; Guo, G; Wu, QY; Xu, S	1
Comoglu, SS; Guven, H; Kocer, B	1
Feng, H; Peng, S; Xiao, J; Xie, Y; Zhang, J	1
Herrman, L; Kinkel, M; Muhlack, S; Müller, T	1
Kang, K; Ko, PW; Lee, HW; Park, D; Park, JS	1
Andréasson, M; Brodin, L; Laffita-Mesa, JM; Svenningsson, P	1
Čierny, D; Grofik, M; Kurča, E; Michalik, J; Nosáľ, V; Sivák, Š; Tatarková, Z; Turčanová Koprušáková, M	1
Dong, Q; Fang, L; Li, J; Liao, J; Lu, T; Lu, Z; Peng, F; Qin, F; Qiu, W; Sun, X; Xu, X	1
Jadavji, NM; Murray, LK	1
Chen, L; Gu, C; Li, D; Li, J; Zhu, M; Zhu, X	1
Baik, JS; Lee, JJ	1
Anamnart, C; Kitjarak, R	1
de Almeida, AG; Finsterer, J; Rodrigues, AM; Scorza, CA; Scorza, FA	1
Bai, Y; Gu, R; Jiang, X; Jiang, Y; Pan, Y; Shen, B; Wang, Y; Yan, J; Zhang, L; Zhong, M; Zhu, J; Zhu, S	1
Chen, J; Cheng, XY; Gu, HY; Jin, H; Li, K; Liu, CF; Liu, MH; Mao, CJ; Xiong, YT; Zhang, JR	1
Müller, T; Schlegel, E; Thiede, HM; Zingler, S	1
Boleková, V; Gmitterová, K; Košutzká, Z; Matejička, P; Minár, M; Valkovič, P	1
Ahlskog, JE	1
Bhidayasiri, R; Garcia-Ruiz, P; Müller, T; Odin, P; Phokaewvarangkul, O; Riederer, P	1
Gao, F; Gao, L; Miao, J; Yang, Y	1

Reviews

17 review(s) available for homocysteine and levodopa

Article	Year
Non-dopaminergic drug treatment of Parkinson's disease. Expert opinion on pharmacotherapy, 2001, Volume: 2, Issue:4 Topics: Adenosine; Adrenergic alpha-Antagonists; Body Weight; Cholinergic Antagonists; Homocysteine; Humans; Levodopa; Methionine; N-Methylaspartate; Parkinson Disease; Piperidines; Serotonin Receptor Agonists	2001
[Treatment with levodopa can affect latent vitamin B 12 and folic acid deficiency. Patients with Parkinson disease runt the risk of elevated homocysteine levels]. Lakartidningen, 2003, Aug-28, Volume: 100, Issue:35 Topics: Animals; Antiparkinson Agents; Biomarkers; Blood-Brain Barrier; Folic Acid Deficiency; Homocysteine; Humans; Levodopa; Parkinson Disease; Vitamin B 12 Deficiency	2003
Methylation demand: a key determinant of homocysteine metabolism. Acta biochimica Polonica, 2004, Volume: 51, Issue:2 Topics: Animals; Creatine; Guanidinoacetate N-Methyltransferase; Homocysteine; Humans; Levodopa; Methylation; Methyltransferases; Models, Biological; Models, Chemical; Parkinson Disease; Phosphatidylcholines; Phosphatidylethanolamine N-Methyltransferase; Rats	2004
Homocysteine and levodopa: should Parkinson disease patients receive preventative therapy? Neurology, 2004, Sep-14, Volume: 63, Issue:5 Topics: Antiparkinson Agents; Arteriosclerosis; Catechol O-Methyltransferase; Dementia; Disease Progression; Disease Susceptibility; Homocysteine; Humans; Hyperhomocysteinemia; Inflammation; Levodopa; Models, Biological; Multicenter Studies as Topic; Oxidative Stress; Parkinson Disease; Randomized Controlled Trials as Topic; Substantia Nigra	2004
Methylation demand and homocysteine metabolism. Advances in enzyme regulation, 2004, Volume: 44 Topics: Animals; Homocysteine; Humans; Levodopa; Methionine Adenosyltransferase; Methylation; Methyltransferases; Niacin; Phosphatidylethanolamine N-Methyltransferase; S-Adenosylmethionine	2004
Is levodopa toxic? Journal of neurology, 2004, Volume: 251 Suppl 6 Topics: Animals; Dose-Response Relationship, Drug; Homocysteine; Humans; Levodopa; Nerve Degeneration; Neurotoxins; Oxidative Stress; Parkinson Disease; Substantia Nigra	2004
Hyperhomocysteinemia in movement disorders: Current evidence and hypotheses. Current vascular pharmacology, 2006, Volume: 4, Issue:3 Topics: Adolescent; Adult; Animals; Case-Control Studies; Catechol O-Methyltransferase; Cystathionine beta-Synthase; Dopamine Agents; Dystonia; Homocysteine; Humans; Huntington Disease; Hyperhomocysteinemia; Levodopa; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Movement Disorders; Parkinson Disease; Prospective Studies	2006
Homocysteine and Parkinson's disease: a dangerous liaison? Journal of the neurological sciences, 2007, Jun-15, Volume: 257, Issue:1-2 Topics: Brain; Brain Diseases, Metabolic; Causality; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Nerve Degeneration; Parkinson Disease	2007
Role of homocysteine in the treatment of Parkinson's disease. Expert review of neurotherapeutics, 2008, Volume: 8, Issue:6 Topics: Antiparkinson Agents; Brain; Catechol O-Methyltransferase; Homocysteine; Humans; Levodopa; Parkinson Disease, Secondary	2008
Hyperhomocysteinemia in L-dopa treated patients with Parkinson's disease: potential implications in cognitive dysfunction and dementia? Current medicinal chemistry, 2010, Volume: 17, Issue:28 Topics: Antiparkinson Agents; Cognition Disorders; Dementia; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Neurons; Parkinson Disease	2010
Motor complications, levodopa metabolism and progression of Parkinson's disease. Expert opinion on drug metabolism & toxicology, 2011, Volume: 7, Issue:7 Topics: Animals; Arteriosclerosis; Catechol O-Methyltransferase; Disease Progression; Dopamine; Dyskinesias; Enzyme Inhibitors; Free Radicals; Homocysteine; Humans; Levodopa; Nerve Degeneration; Parkinson Disease; Synaptic Transmission	2011
Elevated homocysteine levels in levodopa-treated idiopathic Parkinson's disease: a meta-analysis. Acta neurologica Scandinavica, 2013, Volume: 128, Issue:2 Topics: Antiparkinson Agents; Databases, Factual; Homocysteine; Humans; Levodopa; Parkinson Disease	2013
[Homocysteine and its role in pathogenesis of Parkinson's disease and other neurodegenerative disorders]. Przeglad lekarski, 2013, Volume: 70, Issue:7 Topics: Catechol O-Methyltransferase Inhibitors; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Neurodegenerative Diseases; Parkinson Disease; Vitamin B Complex	2013
Association of plasma homocysteine, vitamin B12 and folate levels with cognitive function in Parkinson's disease: A meta-analysis. Neuroscience letters, 2017, 01-01, Volume: 636 Topics: Adult; Aged; Aged, 80 and over; Cognition; Cognition Disorders; Female; Folic Acid; Homocysteine; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome; Vitamin B 12	2017
The role of one-carbon metabolism and homocysteine in Parkinson's disease onset, pathology and mechanisms. Nutrition research reviews, 2019, Volume: 32, Issue:2 Topics: Animals; Diet; Folic Acid; Genetic Predisposition to Disease; Homocysteine; Humans; Levodopa; Methylation; Methylenetetrahydrofolate Reductase (NADPH2); Nutritional Status; One-Carbon Group Transferases; Parkinson Disease; Polymorphism, Genetic; Vitamin B Complex	2019
Levodopa, homocysteine and Parkinson's disease: What's the problem? Parkinsonism & related disorders, 2023, Volume: 109 Topics: Antiparkinson Agents; Catechol O-Methyltransferase; Homocysteine; Humans; Levodopa; Parkinson Disease; Vitamin B 12; Vitamin B Complex	2023
Homocysteine, vitamin B metabolites, dopamine-substituting compounds, and symptomatology in Parkinson's disease: clinical and therapeutic considerations. Journal of neural transmission (Vienna, Austria : 1996), 2023, Volume: 130, Issue:11 Topics: Antiparkinson Agents; Catechol O-Methyltransferase; Dopamine; Homocysteine; Humans; Levodopa; Parkinson Disease; Vitamin B 12; Vitamins	2023

Trials

18 trial(s) available for homocysteine and levodopa

Article	Year
Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status. Neurology, 2003, Apr-08, Volume: 60, Issue:7 Topics: Antiparkinson Agents; Female; Folic Acid; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Linear Models; Male; Middle Aged; Parkinson Disease; Pyridoxal Phosphate; Risk Factors; Vitamin B 12; Vitamin B Complex	2003
Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients. Movement disorders : official journal of the Movement Disorder Society, 2005, Volume: 20, Issue:1 Topics: Aged; Antiparkinson Agents; Case-Control Studies; Catechols; Chromatography, High Pressure Liquid; Drug Therapy, Combination; Female; Folic Acid; Homocysteine; Humans; Levodopa; Linear Models; Male; Middle Aged; Nitriles; Parkinson Disease; Vitamin B 12	2005
Plasma homocysteine levels in Parkinson's disease: role of antiparkinsonian medications. Parkinsonism & related disorders, 2005, Volume: 11, Issue:2 Topics: Aged; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Enzyme Inhibitors; Female; Folic Acid; Homocysteine; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Vitamin B 12	2005
The effect of entacapone on homocysteine levels in Parkinson disease. Neurology, 2005, Apr-26, Volume: 64, Issue:8 Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Cohort Studies; Drug Interactions; Drug Therapy, Combination; Enzyme Inhibitors; Female; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Male; Middle Aged; Nitriles; Treatment Outcome	2005
Tolcapone decreases plasma levels of S-adenosyl-L-homocysteine and homocysteine in treated Parkinson's disease patients. European journal of clinical pharmacology, 2006, Volume: 62, Issue:6 Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benzophenones; Catechol O-Methyltransferase Inhibitors; Enzyme Inhibitors; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Prospective Studies; S-Adenosylhomocysteine; Tolcapone	2006
Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson's disease, with and without levodopa therapy. Journal of the neurological sciences, 2006, Oct-25, Volume: 248, Issue:1-2 Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Cysteine; Female; Homocysteine; Humans; Levodopa; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Parkinson Disease; Threonine; Time Factors	2006
Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study. Neurology, 2006, Jun-27, Volume: 66, Issue:12 Topics: Aged; Antiparkinson Agents; Canada; Catechols; Double-Blind Method; Drug Combinations; Female; Folic Acid; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Placebo Effect; Treatment Outcome; United States; Vitamin B 12; Vitamins	2006
Plasma homocysteine levels in patients treated with levodopa: motor and cognitive associations. Neurological research, 2006, Volume: 28, Issue:8 Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Case-Control Studies; Cognition; Enzyme-Linked Immunosorbent Assay; Female; Folic Acid; Homocysteine; Humans; Levodopa; Male; Middle Aged; Motor Activity; Neuropsychological Tests; Parkinson Disease; Statistics, Nonparametric; Vitamin B 12	2006
Effect of levodopa and entacapone treatment on plasma homocysteine levels in Parkinson's disease patients. Parkinsonism & related disorders, 2009, Volume: 15, Issue:6 Topics: Aged; Antiparkinson Agents; Catechols; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease	2009
Hyperhomocysteinemia in levodopa-treated patients with Parkinson's disease dementia. Movement disorders : official journal of the Movement Disorder Society, 2009, May-15, Volume: 24, Issue:7 Topics: Aged; Analysis of Variance; Antiparkinson Agents; Case-Control Studies; Chromatography, High Pressure Liquid; Cross-Sectional Studies; Dementia; Female; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Logistic Models; Male; Mental Status Schedule; Middle Aged; Neuropsychological Tests; Parkinson Disease	2009
Homocysteine levels after acute levodopa intake in patients with Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society, 2009, Jul-15, Volume: 24, Issue:9 Topics: Aged; Analysis of Variance; Antiparkinson Agents; Dihydroxyphenylalanine; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Statistics as Topic; Time Factors; Tyrosine	2009
Use of memantine (akatinol) for the correction of cognitive impairments in Parkinson's disease complicated by dementia. Neuroscience and behavioral physiology, 2010, Volume: 40, Issue:2 Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Cognition; Cognition Disorders; Dementia; Disability Evaluation; Dyskinesias; Homocysteine; Humans; Levodopa; Memantine; Neuropsychological Tests; Nootropic Agents; Parkinson Disease; Psychiatric Status Rating Scales; Receptors, N-Methyl-D-Aspartate; Treatment Outcome	2010
Elevation of total homocysteine levels in patients with Parkinson's disease treated with duodenal levodopa/carbidopa gel. Journal of neural transmission (Vienna, Austria : 1996), 2011, Volume: 118, Issue:9 Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Duodenum; Female; Gels; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Male; Methyldopa; Middle Aged; Parkinson Disease	2011
Inhibition of catechol-O-methyltransferase modifies acute homocysteine rise during repeated levodopa application in patients with Parkinson's disease. Naunyn-Schmiedeberg's archives of pharmacology, 2011, Volume: 383, Issue:6 Topics: Aged; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Biological Availability; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Drug Combinations; Drug Therapy, Combination; Female; Half-Life; Homocysteine; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Tyrosine	2011
Serum homocysteine and physical exercise in patients with Parkinson's disease. Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society, 2011, Volume: 11, Issue:2 Topics: Aged; Antiparkinson Agents; Exercise; Female; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Male; Matched-Pair Analysis; Mental Status Schedule; Middle Aged; Parkinson Disease	2011
Homocysteine Levels in Parkinson's Disease: Is Entacapone Effective? BioMed research international, 2016, Volume: 2016 Topics: Adult; Aged; Aged, 80 and over; Catechol O-Methyltransferase; Catechols; Dopamine Agonists; Female; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Prospective Studies	2016
Effects of vitamin B12, folate, and entacapone on homocysteine levels in levodopa-treated Parkinson's disease patients: A randomized controlled study. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2021, Volume: 88 Topics: Aged; Antiparkinson Agents; Catechols; Female; Folic Acid; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Research Design; Vitamin B 12	2021
Parkinson's disease: Research puts spotlight on thiamine deficiency and cardiovascular health. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2021, Volume: 93 Topics: Folic Acid; Homocysteine; Humans; Levodopa; Parkinson Disease; Thiamine Deficiency; Vitamin B 12	2021

Other Studies

62 other study(ies) available for homocysteine and levodopa

Article	Year
Tropolone antagonism of the L-dopa-induced elevation of S-adenosylhomocysteine: S-adenosylmethionine ratio but not depletion of adrenaline in rat hypothalamus. The Journal of pharmacy and pharmacology, 1984, Volume: 36, Issue:6 Topics: Animals; Catechol O-Methyltransferase Inhibitors; Epinephrine; Homocysteine; Hypothalamus; Levodopa; Male; Rats; Rats, Inbred Strains; S-Adenosylhomocysteine; S-Adenosylmethionine; Tropolone	1984
Effect of L-Dopa and the catechol-O-methyltransferase inhibitor Ro 41-0960 on sulfur amino acid metabolites in rats. Clinical neuropharmacology, 1997, Volume: 20, Issue:1 Topics: Animals; Benzophenones; Brain; Catechol O-Methyltransferase Inhibitors; Cerebellum; Cerebral Cortex; Corpus Striatum; Enzyme Inhibitors; Hippocampus; Homocysteine; Kidney; Levodopa; Liver; Male; Rats; Rats, Sprague-Dawley; S-Adenosylhomocysteine; S-Adenosylmethionine; Spleen	1997
Nigral endothelial dysfunction, homocysteine, and Parkinson's disease. Lancet (London, England), 1999, Jul-10, Volume: 354, Issue:9173 Topics: Aged; Antiparkinson Agents; Carboxy-Lyases; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Substantia Nigra; Vascular Diseases	1999
Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD. Neurology, 2000, Aug-08, Volume: 55, Issue:3 Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Cysteine; Female; Folic Acid; Genotype; Homocysteine; Humans; Levodopa; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Oxidoreductases Acting on CH-NH Group Donors; Parkinson Disease; Point Mutation	2000
Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD. Neurology, 2001, Jan-23, Volume: 56, Issue:2 Topics: Genotype; Homocysteine; Humans; Levodopa; Methylenetetrahydrofolate Reductase (NADPH2); Oxidoreductases Acting on CH-NH Group Donors; Parkinson Disease	2001
Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD. Neurology, 2001, Jan-23, Volume: 56, Issue:2 Topics: Genotype; Homocysteine; Humans; Levodopa; Methylenetetrahydrofolate Reductase (NADPH2); Oxidoreductases Acting on CH-NH Group Donors; Parkinson Disease	2001
Plasma homocysteine and l-dopa metabolism in patients with Parkinson disease. Clinical chemistry, 2001, Volume: 47, Issue:6 Topics: Antiparkinson Agents; Dihydroxyphenylalanine; Dopamine; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Tyrosine	2001
Decrease of methionine and S-adenosylmethionine and increase of homocysteine in treated patients with Parkinson's disease. Neuroscience letters, 2001, Jul-27, Volume: 308, Issue:1 Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Cardiovascular Diseases; Dopa Decarboxylase; Down-Regulation; Drug Interactions; Enzyme Inhibitors; Female; Homocysteine; Humans; Levodopa; Male; Methionine; Middle Aged; Parkinson Disease; S-Adenosylmethionine; Up-Regulation	2001
3-OMD and homocysteine plasma levels in parkinsonian patients. Journal of neural transmission (Vienna, Austria : 1996), 2002, Volume: 109, Issue:2 Topics: Dihydroxyphenylalanine; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Tyrosine	2002
Elevated plasma homocysteine levels in patients treated with levodopa: association with vascular disease. Archives of neurology, 2003, Volume: 60, Issue:1 Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Coronary Artery Disease; Female; Folic Acid; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Male; Middle Aged; Parkinson Disease; Risk Factors; Vitamin B 12	2003
Hypertrophy of IMC of carotid artery in Parkinson's disease is associated with L-DOPA, homocysteine, and MTHFR genotype. Journal of the neurological sciences, 2003, Mar-15, Volume: 207, Issue:1-2 Topics: Aged; Analysis of Variance; Carotid Arteries; Female; Homocysteine; Humans; Hypertrophy; Levodopa; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Oxidoreductases Acting on CH-NH Group Donors; Parkinson Disease; Statistics, Nonparametric; Tunica Intima; Ultrasonography	2003
Levodopa-induced hyperhomocysteinaemia in Parkinson's disease. Acta neurologica Scandinavica, 2003, Volume: 108, Issue:1 Topics: Antiparkinson Agents; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Parkinson Disease	2003
Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status. Neurology, 2004, Feb-24, Volume: 62, Issue:4 Topics: Antiparkinson Agents; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Methylation; Parkinson Disease; S-Adenosylmethionine; Vitamin B Complex	2004
Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status. Neurology, 2004, Feb-24, Volume: 62, Issue:4 Topics: Antiparkinson Agents; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Neopterin; Parkinson Disease; Vitamin B Complex	2004
Levodopa elevates homocysteine: is this a problem? Archives of neurology, 2004, Volume: 61, Issue:5 Topics: Antiparkinson Agents; Brain; Homocysteine; Humans; Levodopa; Parkinson Disease; Peripheral Nervous System Diseases; S-Adenosylmethionine	2004
Levodopa-associated increase of homocysteine levels and sural axonal neurodegeneration. Archives of neurology, 2004, Volume: 61, Issue:5 Topics: Action Potentials; Aged; Antiparkinson Agents; Axons; Chromatography, High Pressure Liquid; Electrophysiology; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Nerve Degeneration; Neural Conduction; Parkinson Disease; Sural Nerve	2004
The COMT inhibitor, entacapone, reduces levodopa-induced elevations in plasma homocysteine in healthy adult rats. Journal of neural transmission (Vienna, Austria : 1996), 2005, Volume: 112, Issue:9 Topics: Animals; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Catechols; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Homocysteine; Hyperhomocysteinemia; Levodopa; Male; Nitriles; Rats; Rats, Wistar	2005
Hyperhomocysteinemia in L-dopa treated Parkinson's disease patients: effect of cobalamin and folate administration. European journal of neurology, 2005, Volume: 12, Issue:5 Topics: Aged; Antiparkinson Agents; Female; Folic Acid; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Male; Middle Aged; Parkinson Disease; Vitamin B 12	2005
Reduced plasma homocysteine levels in levodopa/entacapone treated Parkinson patients. Parkinsonism & related disorders, 2005, Volume: 11, Issue:4 Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Cross-Sectional Studies; Drug Therapy, Combination; Enzyme Inhibitors; Female; Folic Acid; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Vitamin B 12	2005
Endothelial function markers in parkinsonian patients with hyperhomocysteinemia. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2005, Volume: 12, Issue:6 Topics: Aged; Analysis of Variance; Antiparkinson Agents; Biomarkers; Case-Control Studies; E-Selectin; Endothelium, Vascular; Fasting; Female; Homocysteine; Humans; Hyperhomocysteinemia; Intercellular Adhesion Molecule-1; Levodopa; Male; Middle Aged; Nitric Oxide; Parkinson Disease; Superoxide Dismutase	2005
Plasma homocysteine levels in L-dopa-treated Parkinson's disease patients with cognitive dysfunctions. Clinical chemistry and laboratory medicine, 2005, Volume: 43, Issue:10 Topics: Aged; Case-Control Studies; Cognition Disorders; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Parkinson Disease	2005
RETRACTED: Homocysteine as a predictive factor for hip fracture in elderly women with Parkinson's disease. The American journal of medicine, 2005, Volume: 118, Issue:11 Topics: Accidental Falls; Aged; Antiparkinson Agents; Cohort Studies; Female; Follow-Up Studies; Fractures, Spontaneous; Hip Fractures; Homocysteine; Humans; Hyperhomocysteinemia; Immobilization; Incidence; Japan; Levodopa; Osteoporosis; Parkinson Disease; Proportional Hazards Models; Risk Factors	2005
Association of homocysteine with plasma amyloid beta protein in aging and neurodegenerative disease. Neurology, 2005, Nov-08, Volume: 65, Issue:9 Topics: Aged; Aged, 80 and over; Aging; Alzheimer Disease; Amyloid beta-Peptides; Brain; Causality; Cerebral Amyloid Angiopathy; Cognition Disorders; Creatinine; Female; Folic Acid; Homocysteine; Humans; Levodopa; Male; Memory Disorders; Middle Aged; Neurodegenerative Diseases; Parkinson Disease; Predictive Value of Tests; Vitamin B 12	2005
Elevated plasma homocysteine levels in L-dopa-treated Parkinson's disease patients with dyskinesias. Clinical chemistry and laboratory medicine, 2006, Volume: 44, Issue:7 Topics: Cross-Sectional Studies; Dyskinesias; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Parkinson Disease	2006
Hyperhomocysteinemia and methylenetetrahydrofolate reductase polymorphism in patients with Parkinson's disease. Neuroscience letters, 2006, Aug-14, Volume: 404, Issue:1-2 Topics: Adult; Aged; Aged, 80 and over; Folic Acid; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Parkinson Disease; Polymorphism, Single Nucleotide; Reference Values; Vitamin B 12	2006
Nitrous oxide promotes hyperhomocysteinemia in levodopa treated rats. Parkinsonism & related disorders, 2007, Volume: 13, Issue:8 Topics: Analgesics, Non-Narcotic; Analysis of Variance; Animals; Catechols; Drug Interactions; Enzyme Inhibitors; Homocysteine; Hyperhomocysteinemia; Immunoassay; Levodopa; Male; Nitriles; Nitrous Oxide; Random Allocation; Rats; Rats, Wistar	2007
Neurotoxicity of levodopa: treatment-associated homocysteine increase. Nature clinical practice. Neurology, 2007, Volume: 3, Issue:6 Topics: Animals; Antiparkinson Agents; Homocysteine; Humans; Levodopa; Parkinson Disease	2007
Homocysteine in restless legs syndrome. Sleep medicine, 2008, Volume: 9, Issue:4 Topics: Aged; Antiparkinson Agents; Catechols; Female; Folic Acid; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Reference Values; Restless Legs Syndrome; Vitamin B 12; Vitamin B 6	2008
Effect of MTHFR polymorphisms on hyperhomocysteinemia in levodopa-treated Parkinsonian patients. Neuromolecular medicine, 2007, Volume: 9, Issue:3 Topics: Aged; Antiparkinson Agents; Female; Folic Acid; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Parkinson Disease; Polymorphism, Genetic; Vitamin B 12	2007
Neuropathy as a potential complication of levodopa use in Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society, 2008, Oct-15, Volume: 23, Issue:13 Topics: Analysis of Variance; Antiparkinson Agents; Female; Homocysteine; Humans; Levodopa; Male; Methylmalonic Acid; Parkinson Disease; Peripheral Nervous System Diseases; Retrospective Studies; Vitamin B 12	2008
Homocysteine is not associated with global motor or cognitive measures in nondemented older Parkinson's disease patients. Movement disorders : official journal of the Movement Disorder Society, 2009, Jan-30, Volume: 24, Issue:2 Topics: Aged; Antiparkinson Agents; Cognition; Creatinine; Female; Folic Acid; Genotype; Homocysteine; Humans; Inactivation, Metabolic; Levodopa; Male; Methylation; Methylenetetrahydrofolate Reductase (NADPH2); Motor Skills; Neuropsychological Tests; Parkinson Disease; Severity of Illness Index; Vitamin B Complex	2009
Evidence that folic acid deficiency is a major determinant of hyperhomocysteinemia in Parkinson's disease. Metabolic brain disease, 2009, Volume: 24, Issue:2 Topics: Analysis of Variance; Case-Control Studies; Female; Folic Acid; Folic Acid Deficiency; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Male; Matched-Pair Analysis; Middle Aged; Nerve Degeneration; Parkinson Disease; Reference Values; Statistics, Nonparametric; Vitamin B 12	2009
Peripheral COMT inhibition prevents levodopa associated homocysteine increase. Journal of neural transmission (Vienna, Austria : 1996), 2009, Volume: 116, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Delayed-Action Preparations; Dihydroxyphenylalanine; Enzyme Inhibitors; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Time Factors; Tyrosine	2009
Methylenetetrahydrofolate reductase polymorphisms and plasma homocysteine in levodopa-treated and non-treated Parkinson's disease patients. Journal of the neurological sciences, 2009, Dec-15, Volume: 287, Issue:1-2 Topics: Age Distribution; Aged; Aged, 80 and over; Amino Acid Substitution; Antiparkinson Agents; Base Sequence; Biomarkers; DNA Mutational Analysis; Female; Gene Frequency; Genetic Markers; Genetic Predisposition to Disease; Genetic Testing; Genotype; Homocysteine; Humans; Levodopa; Male; Methylenetetrahydrofolate Dehydrogenase (NAD+); Parkinson Disease; Polymorphism, Genetic; Sex Distribution	2009
Impaired transmethylation potential in Parkinson's disease patients treated with L-Dopa. Neuroscience letters, 2010, Jan-14, Volume: 468, Issue:3 Topics: Aged; Antiparkinson Agents; Cross-Sectional Studies; Erythrocytes; Female; Genotype; Homocysteine; Humans; Levodopa; Male; Methylation; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Parkinson Disease; Polymorphism, Genetic; S-Adenosylhomocysteine; S-Adenosylmethionine	2010
Hyperhomocysteinemia due to levodopa treatment as a risk factor for osteoporosis in patients with Parkinson's disease. Calcified tissue international, 2010, Volume: 86, Issue:2 Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Bone and Bones; Bone Density; Causality; Cohort Studies; Comorbidity; Female; Fractures, Bone; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Male; Middle Aged; Osteoporosis; Prevalence; Risk Factors; Up-Regulation	2010
Hyperhomocysteinemia recurrence in levodopa-treated Parkinson's disease patients. European journal of neurology, 2010, Volume: 17, Issue:5 Topics: Aged; Cross-Sectional Studies; Dopamine Agents; Female; Genetic Predisposition to Disease; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Secondary Prevention; Treatment Outcome; Vitamin B 12	2010
L-Dopa therapy increases homocysteine concentration in cerebrospinal fluid from patients with Parkinson's disease. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2010, Volume: 17, Issue:6 Topics: Aged; Antiparkinson Agents; Case-Control Studies; Female; Homocysteine; Humans; Levodopa; Male; Methionine; Middle Aged; Parkinson Disease; Statistics, Nonparametric	2010
Effect of entacapone on plasma homocysteine levels in Parkinson's disease patients. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2010, Volume: 31, Issue:5 Topics: Aged; Antiparkinson Agents; Catechols; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Time Factors	2010
Levodopa and 3-OMD levels in Parkinson patients treated with Duodopa. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2010, Volume: 20, Issue:10 Topics: Antiparkinson Agents; Drug Therapy, Combination; Duodenum; Female; Home Infusion Therapy; Homocysteine; Humans; Infusions, Parenteral; Levodopa; Male; Methyldopa; Parkinson Disease	2010
Acute homocysteine rise after repeated levodopa application in patients with Parkinson's disease. Parkinsonism & related disorders, 2010, Volume: 16, Issue:10 Topics: Antiparkinson Agents; Area Under Curve; Circadian Rhythm; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Risk Factors; Vitamins	2010
Coenzyme Q10, hyperhomocysteinemia and MTHFR C677T polymorphism in levodopa-treated Parkinson's disease patients. Neuromolecular medicine, 2012, Volume: 14, Issue:1 Topics: Aged; Antiparkinson Agents; Female; Folic Acid; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Parkinson Disease; Polymorphism, Genetic; Ubiquinone; Vitamin B 12	2012
Elevated homocysteine by levodopa is detrimental to neurogenesis in parkinsonian model. PloS one, 2012, Volume: 7, Issue:11 Topics: Animals; Blotting, Western; Dopamine Agonists; Flow Cytometry; Homocysteine; Immunohistochemistry; Levodopa; Male; Mice; Mice, Inbred C57BL; Neurogenesis; Parkinson Disease; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction	2012
[Effects of entacapone on plasma homocysteine in Parkinson's disease patients on levodopa]. Zhonghua yi xue za zhi, 2013, Feb-19, Volume: 93, Issue:7 Topics: Aged; Catechols; Cross-Sectional Studies; Female; Homocysteine; Humans; Levodopa; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Nitriles; Parkinson Disease	2013
Neuropathy and levodopa in Parkinson's disease: evidence from a multicenter study. Movement disorders : official journal of the Movement Disorder Society, 2013, Volume: 28, Issue:10 Topics: Aged; Antiparkinson Agents; Female; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Logistic Models; Male; Middle Aged; Neural Conduction; Parkinson Disease; Peripheral Nervous System Diseases; Prevalence; Risk; Vitamin B 12	2013
Prevalence and features of peripheral neuropathy in Parkinson's disease patients under different therapeutic regimens. Parkinsonism & related disorders, 2014, Volume: 20, Issue:1 Topics: Aged; Antiparkinson Agents; Cross-Sectional Studies; Electromyography; Female; Folic Acid; Homocysteine; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Peripheral Nervous System Diseases; Prevalence; Vitamin B 12	2014
Association of homocysteine with ventricular dilatation and brain atrophy in Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society, 2014, Volume: 29, Issue:3 Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Atrophy; Brain; Dilatation; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Parkinson Disease	2014
Endothelial dysfunction and hyperhomocysteinemia in Parkinson's disease: flow-mediated dilation study. Movement disorders : official journal of the Movement Disorder Society, 2014, Volume: 29, Issue:12 Topics: Aged; Antiparkinson Agents; Brachial Artery; Catechols; Dilatation; Endothelium; Female; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Logistic Models; Male; Middle Aged; Nitriles; Parkinson Disease; Statistics, Nonparametric	2014
L-DOPA treatment in MPTP-mouse model of Parkinson's disease potentiates homocysteine accumulation in substantia nigra. Neuroscience letters, 2016, 08-15, Volume: 628 Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopaminergic Neurons; Homocysteine; Levodopa; Male; Mice; Motor Activity; Parkinsonian Disorders; Substantia Nigra; Tyrosine 3-Monooxygenase	2016
The effect of levodopa benserazide hydrochloride on homocysteinemia levels in patients with Parkinson's disease and treatment of hyperhomocysteinemia. European review for medical and pharmacological sciences, 2016, Volume: 20, Issue:11 Topics: Antiparkinson Agents; Benserazide; Dopamine Agents; Drug Combinations; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Parkinson Disease	2016
Levodopa, placebo and rotigotine change biomarker levels for oxidative stress. Neurological research, 2017, Volume: 39, Issue:5 Topics: Aged; Analysis of Variance; Chromatography, High Pressure Liquid; Dihydroxyphenylalanine; Dipeptides; Dopamine Agents; Electrochemical Techniques; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Oxidative Stress; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes; Time Factors; Tyrosine	2017
Serum methylmalonic acid correlates with neuropathic pain in idiopathic Parkinson's disease. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2017, Volume: 38, Issue:10 Topics: Aged; Antiparkinson Agents; Biomarkers; Cross-Sectional Studies; Female; Homocysteine; Humans; Levodopa; Male; Methylmalonic Acid; Middle Aged; Neural Conduction; Neuralgia; Pain Measurement; Parkinson Disease; Prevalence; Severity of Illness Index; Vitamin B 12	2017
Correlations Between Methionine Cycle Metabolism, COMT Genotype, and Polyneuropathy in L-Dopa Treated Parkinson's Disease: A Preliminary Cross-Sectional Study. Journal of Parkinson's disease, 2017, Volume: 7, Issue:4 Topics: Aged; Catechol O-Methyltransferase; Cognition Disorders; Cross-Sectional Studies; Female; Genotype; Homocysteine; Humans; Levodopa; Male; Methionine; Middle Aged; Neuropsychological Tests; Parkinson Disease; Polymorphism, Single Nucleotide; Polyneuropathies; Statistics, Nonparametric; Vitamins	2017
The influence of levodopa, entacapone and homocysteine on prevalence of polyneuropathy in patients with Parkinson's disease. Journal of the neurological sciences, 2018, 09-15, Volume: 392 Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Case-Control Studies; Catechols; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Polyneuropathies; Statistics, Nonparametric	2018
Clinical utility of SUDOSCAN in predicting autonomic neuropathy in patients with Parkinson's disease. Parkinsonism & related disorders, 2019, Volume: 64 Topics: Aged; Antiparkinson Agents; Autonomic Nervous System Diseases; Electrophysiology; Female; Galvanic Skin Response; Homocysteine; Humans; Levodopa; Male; Middle Aged; Parkinson Disease	2019
Correlations between blood lipid, serum cystatin C, and homocysteine levels in patients with Parkinson's disease. Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society, 2020, Volume: 20, Issue:2 Topics: Aged; Aged, 80 and over; Case-Control Studies; Cystatin C; Female; Homocysteine; Humans; Levodopa; Lipids; Male; Middle Aged; Parkinson Disease; Risk Factors; Triglycerides	2020
Peripheral Neuropathy in Yonsei medical journal, 2020, Volume: 61, Issue:12 Topics: Adult; Aged; Case-Control Studies; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Neural Conduction; Parkinson Disease; Peripheral Nervous System Diseases; Prevalence; Risk Factors; Uric Acid; Vitamin B 12	2020
Elevation of Plasma Homocysteine and Minor Hallucinations in Parkinson's Disease: A Cross-Sectional Study. Behavioural neurology, 2022, Volume: 2022 Topics: Cross-Sectional Studies; Female; Hallucinations; Homocysteine; Humans; Levodopa; Male; Parkinson Disease	2022
Fiber selectivity of peripheral neuropathy in patients with Parkinson's disease. Acta neurologica Scandinavica, 2022, Volume: 146, Issue:1 Topics: Antiparkinson Agents; Homocysteine; Humans; Levodopa; Parkinson Disease; Peripheral Nervous System Diseases	2022
Effects of One-Day Application of Levodopa/Carbidopa/Entacapone versus Levodopa/Carbidopa/Opicapone in Parkinson's Disease Patients. Cells, 2022, 04-30, Volume: 11, Issue:9 Topics: Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Carbidopa; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Homocysteine; Humans; Levodopa; Nitriles; Oxadiazoles; Parkinson Disease	2022
Tolcapone improves outcomes in patients with Parkinson disease treated by levodopa/carbidopa intestinal gel: A pilot study. Medicine, 2022, Aug-12, Volume: 101, Issue:32 Topics: Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase; Drug Combinations; Homocysteine; Humans; Levodopa; Parkinson Disease; Pilot Projects; Quality of Life; Tolcapone	2022
Effects of rasagiline combined with levodopa and benserazide hydrochloride on motor function and homocysteine and IGF-1 levels in elderly patients with Parkinson's disease. BMC neurology, 2023, Oct-06, Volume: 23, Issue:1 Topics: Aged; Antiparkinson Agents; Benserazide; Homocysteine; Humans; Insulin-Like Growth Factor I; Levodopa; Middle Aged; Parkinson Disease	2023